Category Archives: Global News Feed

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options

See the original post:
ARCA biopharma Announces Third Quarter 2022 Financial Results

NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari received a letter from Nasdaq Listing Qualifications indicating that Akari is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Read the rest here:
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) --  BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended August 31, 2022. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us.

Continued here:
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022

SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.

More:
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022

PORTLAND, Ore., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, announces that its interim Chief Financial Officer (CFO), Richard Lindsay, has resigned his position. Mr. Lindsay joined the company in an interim contract role to help get the Company through the 2021 audit. He has accomplished the majority of the work related to the audit and accordingly has resigned his position.

Read the original post:
Chalice Brands Ltd. Announces Resignation of Interim Chief Financial Officer

Conference call to begin at 4:30 p.m. ET

View post:
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Read the original post:
Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2022 Results

BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been accepted for presentation at the American Society of Nephrology (ASN) annual meeting being held in Orlando, Florida, November 3 – 6.

Read more:
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference

Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board

See the original post here:
CytoDyn Announces Appointment of Additional Directors with Industry Experience

LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii.

Go here to read the rest:
T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel